Victoria Socha

DocwireNews

The management of patients with hyponatremia in cardiac cirrhosis is challenging. Palliative care for patients with single ventricle congenital heart lesions includes Fontan surgery that diverts blood from the great veins to the pulmonary arteries, bypassing the right ventricle. Managing patients who develop elevated central venous pressure and cardiac cirrhosis with hyponatremia commonly includes a combination of loop diuretics and mineralocorticoid receptor antagonists.
During a poster session at ASN Kidney Week 2024, Prashant N. Bhenswala, MD, and colleagues at Northwell Health, New Hyde Park, New York, presented a case report of a patient with refractory fluid overload and hyponatremia requiring treatment with tolvaptan. The poster was titled Low-Dosage Tolvaptan for Refractory Hyponatremia in Fontan-Associated Cardiac Cirrhosis.
The male patient was 45 years of age and had undergone Fontan procedure complicated by Fontan-associated liver disease that required paracenteses every 3 weeks. He presented to the emergency department with serum sodium concentration of 122 mEq/L. He was being treated with water restriction and maximally tolerated diuretics (40 mg furosemide and 25 mg spironolactone daily), but the hyponatremia persisted and required more frequent paracenteses and hospitalizations.
Results of physical examination revealed blood pressure of 85/48 mm Hg and ascites and anasarca. His serum osmolality was 266 mosmol/kg. Results of laboratory urine testing showed sodium 7 mmol/L, potassium 45 mmol/L, and osmolality 628 mosm/kg, suggesting antidiuretic hormone-mediated hyponatremia. Low dose tolvaptan was administered despite his history of cirrhosis.
Over four days, the patient’s serum sodium level appropriately increased from 125 mEq/L to 135 mEq/L. He was discharged on tolvaptan 7.5 mg once a week in combination with his home diuretics. He has remained stable with a serum sodium concentration of 130 to 133 mEq/L. The need for hospitalizations and paracenteses has decreased, and serum creatinine remains stable at 1.2 mg/dL.
Due to the risk of liver failure and variceal bleed, recommendations for the use of tolvaptan suggest avoiding use in patients with cirrhosis. In this case, due to the refractory nature of the patient’s hyponatremia and limited therapeutic alternatives, low dose tolvaptan was initiated. The treatment resulted in controlled and sustained correction of serum sodium level and reduction in hospitalizations.
The researchers said, “Tolvaptan should be considered as an alternative therapy for refractory hyponatremia in cirrhosis. Altered pharmacokinetics of the drug in cirrhosis may enable use of a lower dose and frequency for the same effect with no appreciable adverse events.”
Source: Bhenswala P, Upadrista PK, Sharma PD. Low-dosage tolvaptan for refractory hyponatremia in Fontan-associated cardiac cirrhosis. Th-PO340. Abstract of a poster presented at the American Society of Nephrology Kidney Week 2024; October 24, 2024; San Diego, California.

Emily Menendez

Complete Response to Immunotherapy in HCC: Insights From IMbrave150

Hepatocellular Carcinoma

Anne Marie Morse, DO

Rob Dillard

Dr. Morse Talks About the Significance of World Sleep Day 2025

Sleep Disorders

Dr. John Fruehauf, Evolent

Advancing Therapies Have Improved the Prognosis of Metastatic Melanoma

Melanoma

Latest News

Case Report: Patient With Hyponatremia and Fontan-Associated Cardiac Cirrhosis

ASN Kidney Week 2024

Contrary to recommendations, low-dose tolvaptan may be an option for refractory hyponatremia in cirrhosis.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe